W as J.P. Morgan a drag? Is it time to quit on Aduhelm? And the number of guitars is a lot of?
We cover all that and more today on “The Readout LOUD,” STAT’s biotech podcast. Initially, STAT health tech reporter Katie Palmer joins us to wrap up the J.P. Morgan Health Care Conference. Then, we talk about the most recent twist in Biogen’s mission to broaden making use of Aduhelm and what it implies for the treatment of Alzheimer’s illness. Lastly, Arrakis Rehabs CEO Michael Gilman hires to discuss how targeting RNA can deal with illness and why the characters in “Dune” do not simply shoot each other with laser weapons.
For more on what we cover, here’s a take a look at J.P. Morgan; here’s the most recent on Aduhelm; here’s more on Arrakis; here’s where you can register for the First Viewpoint Podcast; and here’s our total protection of the Covid-19 pandemic.
Make sure to register on Apple Podcasts, Stitcher, Google Play, or any place you get your podcasts.
And if you have any feedback for us– subjects to cover, visitors to welcome, singing tics to stop– you can email [email protected].
Intrigued in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected]